Anshul Thakral is the Chief Executive Officer of Fortrea Holdings Inc., a global contract research organization (CRO) spun off from Labcorp in 2023, specializing in clinical development and therapeutic commercialization services for the life sciences industry. With more than 25 years of experience in healthcare and clinical research, Thakral brings a proven track record of driving operational excellence, strategic growth, and innovation. His leadership emphasizes patient-centric solutions, advanced technologies like AI and data analytics, and building high-performing teams to accelerate drug development for biopharmaceutical clients worldwide. Before joining Fortrea, Thakral served as President of Global Development at Syneos Health, where he led the company's clinical development division, overseeing a portfolio of services across 110+ countries and managing thousands of clinical trials. Under his tenure, Syneos expanded its capabilities through key acquisitions, enhanced therapeutic expertise in oncology and rare diseases, and achieved double-digit revenue growth. Earlier in his career, he held senior roles at INC Research (later Syneos) as Chief Operating Officer and at PAREXEL International, where he spearheaded business development, global operations, and large-scale Phase I-IV trials, contributing to multimillion-dollar contracts and operational turnarounds. At Fortrea, Thakral has guided the company’s independent launch, focusing on full-service CRO offerings from early-phase research to post-approval commercialization. His achievements include forging strategic partnerships with top pharma innovators, optimizing decentralized trial models for efficiency, and positioning Fortrea as a leader in real-world evidence generation. Thakral’s vision continues to propel Fortrea’s growth, delivering faster, more reliable paths to market for transformative therapies.